OTHER FUNCTIONS TAS::75 0849::TAS; THIS MODIFICATION ADDS FUNDING FOR WA'S 2 AND

其他功能 塔斯马尼亚::75 0849::塔斯马尼亚；

• 批准号: 8862322
• 负责人: EMIL POP
• 金额: $ 8.16万
• 依托单位: ALCHEM LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-21 至 2017-05-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8862322
• 关键词: Analytical Chemistry; Biological; Chemistry; Contracts; Development; Evaluation; Funding; Lead; Libraries; Literature; Methods; Modification; Pharmacodynamics; Procedures; Property; Publishing; Recommendation; Route; Staging; Work; analog; combinatorial; drug development; drug discovery; falls; improved; programs

Provide synthesis support for the early stages of the drug discovery and development program. The compounds assigned for the synthesis originate from the DCTD¿s NExT program and the Biological Evaluation Committee (BEC) recommendations. The synthesis work involved in this contract originates from the above mentioned programs. Synthesis of analogs in order to improve the potencies and pharmacodynamic properties of lead compounds where the core chemistry is either well established or unknown also would fall within the scope of the contract. In addition, the contracts will be utilized to check the purity and identity of selected compounds as needed. The purity and identity of all resynthesized compounds and intermediates will be established by state-of-the-art analytical chemistry methods. The quantities synthesized would generally vary from 200 mg to 100 grams. Under these contracts the successful Offerors may be required to synthesize small combinatorial libraries by parallel synthesis. Outlines of synthetic routes, and more commonly, detailed experimental procedures obtained from the literature, will be available for the majority of the assignments. Development of synthetic methods may be required in those cases where no procedures are available, or when the published methods prove unreliable in practice.

为药物发现和开发计划的早期阶段提供合成支持。指定用于合成的化合物源自 DCTD 的 NExT 计划和生物评估委员会 (BEC) 的建议。本合同涉及的综合工作来源于上述程序。为了提高先导化合物的效力和药效学特性而合成类似物，其中核心化学要么已确定，要么未知，也属于合同范围。此外，合同将用于根据需要检查所选化合物的纯度和特性。所有重新合成的化合物和中间体的纯度和特性将通过最先进的分析化学方法确定。合成的数量通常从 200 毫克到 100 克不等。根据这些合同，成功的要约人可能需要通过并行合成来合成小型组合库。合成路线的概述，以及更常见的是，从文献中获得的详细实验程序，将可用于大多数作业。在没有可用程序的情况下，或者当已发表的方法在实践中被证明不可靠时，可能需要开发合成方法。